MEI Pharma

MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor that has been granted Breakthrough Therapy Designation from the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Our pipeline of drug candidates also includes ME-401 (formerly PWT143), a next-generation oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor. For more, please go to www.meipharma.com.

biotechnology
50-200 employees
San Diego, United States
Founded 2000

About MEI Pharma

MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor that has been granted Breakthrough Therapy Designation from the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Our pipeline of drug candidates also includes ME-401 (formerly PWT143), a next-generation oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor. For more, please go to www.meipharma.com.

Company Details

Business Type privately-held
Revenue $1M-$10M

Social Media

Technologies

apple-business-manager cloudflare-cdn drupal google-analytics google-tag-manager microsoft-365 php

Frequently Asked Questions

What does MEI Pharma do?

MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor that has been granted Breakthrough Therapy Designation from the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Our pipeline of drug candidates also includes ME-401 (formerly PWT143), a next-generation oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor. For more, please go to www.meipharma.com.

How can I contact MEI Pharma?

Visit their website at meipharma.com for more information.

Where is MEI Pharma located?

San Diego, United States

What industry is MEI Pharma in?

biotechnology

How many employees does MEI Pharma have?

50-200

When was MEI Pharma founded?

2000

Looking for More Company Information?

Discover more innovative companies in our comprehensive directory.

Browse All Companies